FormWeb • dalfopristin-quinupristin

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search by class Show Therapeutic Classes

Add Formweb to your mobile device

Android iOS

Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

dalfopristin-quinupristin

dalfopristin-quinupristin

Formulary Miscellaneous Program Formulary

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Synercid	POWDER FOR INJECTION, INTRAVENOUS	350 mg-150 mg

VIEW MORE Streptogramins

Comments:

**NOTE: Pfizer discontinued Synercid in early 2022. There are currently no other suppliers of the product** (Updated April 2023)

Linezolid is the preferred agent.

Last updated: Apr. 10, 2023

Black Box Warning: Approved indication

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.